Pirfenidone	B:C0298067
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	B:C3665472
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	B:C0556530
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	B:C0932050
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	B:C0027651
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	B:C0015350
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	B:C0027651
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	B:C0005847
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	B:C0005847
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	B:C0087111
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	O
therapy	I:C0920425
.	O

Pirfenidone	O
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	O
Normalization	O
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	O
of	O
the	O
tumor	O
extracellular	O
matrix	I:C0015350
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	O
blood	O
vessels	I:C0005847
,	O
increase	O
vessel	O
perfusion	O
and	O
thus	O
,	O
improve	O
drug	O
delivery	I:C0087111
and	O
the	O
efficacy	O
of	O
cancer	B:C0920425
therapy	I:C0920425
.	O

Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	B:C0243095
pharmaceutical	O
agents	I:C1254351
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	O
tumors	I:C0280100
and	O
enhance	O
chemotherapy	O
.	O

Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	O
pharmaceutical	B:C1254351
agents	I:C1254351
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	O
tumors	I:C0280100
and	O
enhance	O
chemotherapy	O
.	O

Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	O
pharmaceutical	O
agents	I:C1254351
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	B:C0280100
tumors	I:C0280100
and	O
enhance	O
chemotherapy	O
.	O

Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	O
pharmaceutical	O
agents	I:C1254351
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	O
tumors	I:C0280100
and	O
enhance	O
chemotherapy	B:C3665472
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
repurposed	O
Pirfenidone	O
,	O
a	O
clinically	O
approved	O
anti-fibrotic	O
drug	O
for	O
the	O
treatment	O
of	O
idiopathic	O
pulmonary	I:C1800706
fibrosis	I:C1800706
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	O
.	O

In	O
this	O
study	O
,	O
we	O
repurposed	O
Pirfenidone	B:C0298067
,	O
a	O
clinically	O
approved	O
anti-fibrotic	O
drug	O
for	O
the	O
treatment	O
of	O
idiopathic	O
pulmonary	I:C1800706
fibrosis	I:C1800706
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	O
.	O

In	O
this	O
study	O
,	O
we	O
repurposed	O
Pirfenidone	O
,	O
a	O
clinically	O
approved	O
anti-fibrotic	O
drug	O
for	O
the	O
treatment	B:C0087111
of	O
idiopathic	O
pulmonary	I:C1800706
fibrosis	I:C1800706
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	O
.	O

In	O
this	O
study	O
,	O
we	O
repurposed	O
Pirfenidone	O
,	O
a	O
clinically	O
approved	O
anti-fibrotic	O
drug	O
for	O
the	O
treatment	O
of	O
idiopathic	B:C1800706
pulmonary	I:C1800706
fibrosis	I:C1800706
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	O
.	O

In	O
this	O
study	O
,	O
we	O
repurposed	O
Pirfenidone	O
,	O
a	O
clinically	O
approved	O
anti-fibrotic	O
drug	O
for	O
the	O
treatment	O
of	O
idiopathic	O
pulmonary	I:C1800706
fibrosis	I:C1800706
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	B:C0556530
.	O

Using	O
two	O
orthotopic	B:C0574893
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	B:C0006141
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	B:C1710493
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	B:C0298067
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	B:C0009325
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	B:C0813622
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	B:C0005847
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	O
.	O

Using	O
two	O
orthotopic	O
mammary	O
tumor	O
models	I:C1710493
we	O
demonstrate	O
that	O
Pirfenidone	O
reduces	O
collagen	O
and	O
hyaluronan	O
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	O
vessel	I:C0005847
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti-tumor	O
efficacy	O
of	O
doxorubicin	B:C0013089
.	O

Reduction	O
of	O
extracellular	B:C0932050
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	B:C0013081
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	B:C1366557
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	B:C1332772
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	B:C1413581
,	O
HAS2	O
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	B:C1415475
,	O
HAS3	O
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	B:C1415476
expression	O
levels	O
.	O

Reduction	O
of	O
extracellular	O
matrix	I:C0932050
components	I:C0932050
were	O
mediated	O
via	O
TGF	O
β	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	O
of	O
TGF	O
β1	I:C1366557
,	O
COL1A1	O
,	O
COL3A1	O
,	O
HAS2	O
,	O
HAS3	O
expression	B:C0017262
levels	O
.	O

Our	O
findings	B:C0243095
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	O
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	O
delivery	I:C0087111
to	O
solid	O
tumors	I:C0280100
by	O
normalizing	O
the	O
tumor	O
microenvironment	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	B:C0298067
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	O
delivery	I:C0087111
to	O
solid	O
tumors	I:C0280100
by	O
normalizing	O
the	O
tumor	O
microenvironment	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	O
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B:C0035171
to	O
enhance	O
drug	O
delivery	I:C0087111
to	O
solid	O
tumors	I:C0280100
by	O
normalizing	O
the	O
tumor	O
microenvironment	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	O
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	B:C0087111
delivery	I:C0087111
to	O
solid	O
tumors	I:C0280100
by	O
normalizing	O
the	O
tumor	O
microenvironment	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	O
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	O
delivery	I:C0087111
to	O
solid	B:C0280100
tumors	I:C0280100
by	O
normalizing	O
the	O
tumor	O
microenvironment	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	O
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	O
to	O
enhance	O
drug	O
delivery	I:C0087111
to	O
solid	O
tumors	I:C0280100
by	O
normalizing	B:C0556530
the	O
tumor	O
microenvironment	O
.	O

